Sarilumab SAR153191 + Sarilumab matching placebo + Prednisone + Prednisone matching placebo

Phase 3Terminated

0 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Giant Cell Arteritis

Conditions

Giant Cell Arteritis

Trial Timeline

Nov 20, 2018 → Nov 24, 2020

NCT ID

NCT03600805

About Sarilumab SAR153191 + Sarilumab matching placebo + Prednisone + Prednisone matching placebo

Sarilumab SAR153191 + Sarilumab matching placebo + Prednisone + Prednisone matching placebo is a phase 3 stage product being developed by Sanofi for Giant Cell Arteritis. The current trial status is terminated. This product is registered under clinical trial identifier NCT03600805. Target conditions include Giant Cell Arteritis.

What happened to similar drugs?

5 of 13 similar drugs in Giant Cell Arteritis were approved

Approved (5) Terminated (2) Active (7)

✅PexidartinibDaiichi SankyoApproved

✅Tocilizumab + PrednisoneRocheApproved

✅ValganciclovirRocheApproved

✅DenosumabAmgenApproved

✅XGEVA®AmgenApproved

🔄PexidartinibDaiichi SankyoPhase 3

🔄Upadacitinib + Corticosteroid (CS)AbbViePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03600805	Phase 3	Terminated	Nov 20, 2018	Nov 24, 2020	Giant Cell Arteritis

Competing Products

20 competing products in Giant Cell Arteritis

See all competitors

Product	Company	Stage	Hype Score
prednisone	Kiniksa Pharmaceuticals	Phase 2	29
Pexidartinib	Daiichi Sankyo	Phase 2	39
Pexidartinib	Daiichi Sankyo	Phase 3	44
Pexidartinib	Daiichi Sankyo	Approved	43
Baricitinib	Eli Lilly	Phase 2	35
Upadacitinib + Corticosteroid (CS)	AbbVie	Phase 3	40
dovitinib	Novartis	Phase 2	35
Secukinumab 300 mg, s.c. + Placebo to match Secukinumab, s.c.	Novartis	Phase 3	40
Secukinumab 300 mg, s.c. + Prednisolone + Placebo	Novartis	Phase 2	35
Secukinumab	Novartis	Phase 1	29
Secukinumab 300 mg + Secukinumab 150 mg	Novartis	Phase 3	40
Tocilizumab + Placebo	Roche	Phase 3	44
Tocilizumab + Prednisone	Roche	Approved	43
Tocilizumab	Roche	Phase 3	40
Tocilizumab	Roche	Phase 1	29
Valganciclovir	Roche	Approved	35
Tocilizumab + Prednisone + Tocilizumab Placebo + Prednisone Placebo + Corticosteroids + Methotrexate	Roche	Phase 3	40
Tocilizumab + Glucocorticoids (GCs) + Placebo + Glucocorticoids (GCs)	Roche	Phase 2	35
tocilizumab and IV steroids combination	Roche	Phase 2	31
Denosumab	Amgen	Approved	43